Elevated cerebrospinal fluid protein in \textit{POLG}-related epilepsy: Diagnostic and prognostic implications

Omar Hikmat\textsuperscript{1,2} | Karin Naess\textsuperscript{3,4} | Martin Engvall\textsuperscript{3,5} | Claus Klingenberg\textsuperscript{6,7} | Magnhild Rasmussen\textsuperscript{8,9} | Chantal M. E. Tallaksen\textsuperscript{10,11} | Eylert Brodtkorb\textsuperscript{12,13} | Torunn Fiskerstrand\textsuperscript{14,15} | Pirjo Isohanni\textsuperscript{16,17} | Johanna Uusimaa\textsuperscript{18,19} | Niklas Darin\textsuperscript{20} | Shamima Rahman\textsuperscript{21,22} | Laurence A. Bindoff\textsuperscript{2,23}

\textsuperscript{1}Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
\textsuperscript{2}Department of Clinical Medicine (K1), University of Bergen, Bergen, Norway
\textsuperscript{3}Center for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden
\textsuperscript{4}Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden
\textsuperscript{5}Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden
\textsuperscript{6}Department of Pediatric and Adolescent Medicine, University Hospital of North Norway, Tromso, Norway
\textsuperscript{7}Pediatric Research Group, Department of Clinical Medicine, UiT–Arctic University of Norway, Tromso, Norway
\textsuperscript{8}Women and Children’s Division, Department of Clinical Neurosciences for Children, Oslo University Hospital, Oslo, Norway
\textsuperscript{9}Unit for Congenital and Hereditary Neuromuscular Disorders, Department of Neurology, Oslo University Hospital, Oslo, Norway
\textsuperscript{10}Department of Neurology, Oslo University Hospital, Oslo, Norway
\textsuperscript{11}Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
\textsuperscript{12}Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, Norway
\textsuperscript{13}Department of Neurology and Clinical Neurophysiology, St. Olav’s University Hospital, Trondheim, Norway
\textsuperscript{14}Department of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway
\textsuperscript{15}Department of Clinical Science (K2), University of Bergen, Bergen, Norway
\textsuperscript{16}Department of Pediatric Neurology, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
\textsuperscript{17}Research Programs Unit, Molecular Neurology, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
\textsuperscript{18}PEDEGO Research Unit and Biocenter Oulu, University of Oulu, Oulu, Finland
\textsuperscript{19}Department of Children and Adolescents, Medical Research Center, Oulu University Hospital, Oulu, Finland
\textsuperscript{20}Department of Pediatrics, Queen Silvia Children’s Hospital, University of Gothenburg, Gothenburg, Sweden
\textsuperscript{21}Mitochondrial Research Group, University College London Great Ormond Street Institute of Child Health, London, UK
\textsuperscript{22}Metabolic Unit, Great Ormond Street Hospital for Children National Health Service Foundation Trust, London, UK
\textsuperscript{23}Department of Neurology, Haukeland University Hospital, Bergen, Norway

\textbf{Correspondence}
Laurence Bindoff, Department of Neurology, University of Bergen, Haukeland University Hospital, Bergen, Norway.
Email: laurence.bindoff@nevro.uib.no

\textbf{Funding information}
Western Norway Regional Health Authority (Helse-Vest), Grant/Award Number: 911944; Helsinki University Hospital

\textbf{Summary}
\textbf{Objective:} Epilepsy is common in individuals with mutations in \textit{POLG}, the gene encoding the catalytic subunit of the mitochondrial DNA polymerase gamma. Early recognition and aggressive seizure management are crucial for patient survival. Disruption of the blood-brain barrier (BBB) is implicated in various neurological disorders including epilepsy. The aim of this study was to assess whether \textit{POLG}-related disease is associated with BBB dysfunction and what clinical implications this has for patients.
Methods: Our retrospective study used data from 83 patients with pathogenic POLG mutations from 4 countries—Norway, Sweden, Finland, and the United Kingdom. Data were collected using a structured questionnaire. We used the presence of raised cerebrospinal fluid (CSF) protein and a raised CSF-serum ratio of albumin (Q-alb) to evaluate the integrity of the blood-CSF barrier.

Results: Raised CSF protein was found in 70% of patients (n = 58/83) and appeared to be associated with the most severe phenotypes. In those in whom it was measured, the Q-alb ratio was markedly elevated (n = 18). The majority of those with epilepsy (n = 50/66, 76%) had raised CSF protein, and this preceded seizure debut in 75% (n = 15/20). The median survival time from symptom onset for those with raised CSF protein was decreased (13 months) compared to those with normal CSF protein (32 months).

Significance: Our results indicate that there is disruption of the BBB in POLG-related disease, as evidenced by a raised CSF protein and Q-alb ratio. We also find that raised CSF protein is a common finding in patients with POLG disease. Our data suggest that the presence of BBB dysfunction predicts a poorer outcome, and elevated CSF protein may therefore be an additional biomarker both for early diagnosis and to identify those at high risk of developing epilepsy.

Key Points
- Epilepsy is very common in individuals with POLG disease and associated with high morbidity and mortality
- Mutations in POLG are associated with progressive disruption of the blood-brain barrier
- Raised CSF protein is commonly seen in patients with POLG disease, especially in those with severe phenotypes
- CSF protein can be used as a biomarker to identify those with high risk of developing epilepsy

1 | INTRODUCTION

Mitochondria perform a number of important functions, including a major role in energy metabolism. Oxidative phosphorylation (OXPHOS), the enzyme pathway responsible for adenosine triphosphate (ATP) production, contains 13 subunits encoded by mitochondrial DNA (mtDNA), whereas the remaining subunits, together with >1000 other proteins required for mitochondrial structure and function, are encoded in the nuclear DNA. The diagnosis of mitochondrial disorders remains challenging, and currently no effective treatments exist for the majority of these disorders.

POLG is a nuclear gene that encodes the catalytic subunit of DNA polymerase γ, the enzyme responsible for mtDNA replication and repair. Mutations in POLG cause disease that varies in severity from devastating infantile phenotypes such as Alpers syndrome and myocerebrohepatopathy spectrum (MCHS) to juvenile syndromes comprising epilepsy and ataxia and to late onset myopathies with progressive external ophthalmoplegia (PEO). Epilepsy is particularly common in the early childhood and juvenile groups, focal seizures, commonly evolving into bilateral convulsive seizures, are the most common seizure types in both adult and pediatric patients, with epileptiform discharges predominantly occurring over the occipital regions. The majority of the patients develop therapy-resistant epilepsy.
the pathophysiology of various acute and chronic neurological disorders (Table 1).15–19

OXPHOS deficiency in central nervous system microvasculature, including vascular smooth muscle cell layer and endothelial cells, has been reported previously.20–22 Evidence of BBB dysfunction, with plasma protein extravasation, has been suggested by the findings of raised CSF protein,3 but has only been demonstrated on postmortem examination in a single patient with POLG disease.22

Given that POLG-related disease causes both a progressive encephalopathy and aggressive epilepsy, the aims of this study were to investigate whether BBB dysfunction occurs in POLG disease and, if so, what the consequences are for affected patients. Our rationale was that greater understanding of the mechanisms driving POLG-related disease has the potential to provide us with both new biomarkers to facilitate earlier diagnosis and novel therapeutic targets.

2 | MATERIALS AND METHODS

2.1 | Study design and population

We conducted a multinational, retrospective study of patients from 9 centers in 4 European countries: Norway (Haukeland University Hospital, Oslo University Hospital, St. Olav’s Hospital, and University Hospital of Northern Norway), the United Kingdom (Great Ormond Street Hospital), Sweden (Center for Inherited Metabolic Diseases, Karolinska University Hospital and Queen Silvia Children’s Hospital, University of Gothenburg), and Finland (Children’s Hospital and University Hospital, Helsinki and Department of Children and Adolescents, Oulu University Hospital). Patients from these centers with pathogenic POLG mutations were included.

Patients were classified phenotypically into 6 groups, including (1) Alpers syndrome; (2) MCHS; (3) myoclonic epilepsy, myopathy, sensory ataxia (MEMSA); (4) ataxia neuropathy spectrum (ANS); and (5) autosomal dominant and autosomal recessive progressive external ophthalmoplegia. Classification was based on previously described criteria.6,23 Patients who did not fulfil the clinical criteria for the above phenotypes were reported as (6) “other.” The study cohort as a whole was also classified into 2 groups according to the presence or absence of epilepsy. Therapy-resistant epilepsy was defined using the International League against Epilepsy definition.24

Ethical approval was obtained from the Regional Committee for Medical and Health Research Ethics, Western Norway (REK 2014/1783-4). Each participating center also
obtained approval from its local ethical committee. The study was registered as an audit at Great Ormond Street Hospital, London, UK.

2.2 | Clinical and laboratory data

Patient’s data were collected using an electronic case report form. Clinical data included age at onset of symptoms requiring medical evaluation, detailed medical history, phenotype, and survival status or date of last follow-up.

Laboratory data included hepatic aminotransferase, blood and CSF lactate, muscle respiratory chain enzyme activities, muscle histology findings, and genetic findings. CSF protein and/or albumin values at disease onset and during the disease course were recorded. Because the reference range for CSF protein may be age dependent, we have looked at the values according to age, and the cutoff values used in this study are reported in Table S1. CSF samples artificially contaminated with blood as a complication of lumbar puncture were not included, and none of the individuals included in this study had clinical or laboratory evidence of meningitis or encephalitis.

Because albumin is produced exclusively in the liver, all albumin detected in CSF originates from blood. The level of CSF albumin provides, therefore, a parameter with which to evaluate the permeability of the blood-CSF barrier. The ratio of CSF to serum albumin (Q-alb) corrects for the individual’s albumin level and provides a reflection of the diffusion gradient of albumin. This ratio was calculated as CSF albumin (mg/L)/serum albumin (g/L). The reference range for Q-alb is age dependent; the cutoffs used in this study are reported in Table S2.

2.3 | Statistical analysis

Data were analyzed using SPSS version 23.0 (Armonk, NY, USA). Results were considered statistically significant with a 2-sided P value of < .05. Survival was defined by the endpoint—time to death, which was defined as the interval in months from the onset of symptoms to the date of death. A comparison of survival time between clinical categories was performed using log-rank test (Kaplan-Meier).

3 | RESULTS

3.1 | Demography

Eighty-three patients, (39 male, 44 female) were identified. Fifty patients were diagnosed in Norway, 19 in Sweden, 9 in the United Kingdom, and 5 in Finland. Median age of onset for the group as a whole was 9 months (range = 3 weeks to 67 years). The majority of patients were Northern European (n = 78), with 3 patients from Iraq and 2 from Cyprus.

3.2 | Phenotype spectrum

Thirty-seven patients fulfilled diagnostic criteria for Alpers, 30 for MEMSA, 8 for ANS, 3 for PEO, 2 for MCHS. Three patients did not fulfill the diagnostic criteria for the

<table>
<thead>
<tr>
<th>Neurological disorder, reference</th>
<th>Q-alb ratio × 10^-3 median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Multiple sclerosis15</td>
<td>4.8 (3.0-10.8)</td>
</tr>
<tr>
<td>Pattern I</td>
<td>7.3 (2.1-33.9)</td>
</tr>
<tr>
<td>Pattern II</td>
<td>9.0 (3.3-20.7)</td>
</tr>
<tr>
<td>Alzheimer's16</td>
<td>5.4 (4.1-7.7)</td>
</tr>
<tr>
<td>Late onset</td>
<td>6.3 (4.9-8.2)</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis17</td>
<td>7 (3-15)</td>
</tr>
<tr>
<td>Parkinson's16</td>
<td>7.4 (5.6-10.5)</td>
</tr>
<tr>
<td>Viral meningitis18</td>
<td>9.1 (7.2-14.7)</td>
</tr>
<tr>
<td>Ischemic stroke19</td>
<td>11.1 (7.8-14.4)</td>
</tr>
<tr>
<td>Territorial</td>
<td>9.7 (7.9-18.5)</td>
</tr>
<tr>
<td>Lacunar</td>
<td>16 (9-55)</td>
</tr>
<tr>
<td>Guillain-Barre syndrome17</td>
<td>17.2 (9.7-28.4)</td>
</tr>
<tr>
<td>Lyme disease18</td>
<td>18 (6-69)</td>
</tr>
<tr>
<td>Bacterial meningitis17</td>
<td>21.5 (14.2-56.8)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Abnormal CSF protein, n (%)</th>
<th>Normal CSF protein, n (%)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpers</td>
<td>30 (81%)</td>
<td>7 (19%)</td>
<td>37</td>
</tr>
<tr>
<td>MCHS</td>
<td>2 (100%)</td>
<td>0 (0%)</td>
<td>2</td>
</tr>
<tr>
<td>MEMSA</td>
<td>20 (67%)</td>
<td>10 (33%)</td>
<td>30</td>
</tr>
<tr>
<td>ANS</td>
<td>4 (50%)</td>
<td>4 (50%)</td>
<td>8</td>
</tr>
<tr>
<td>PEO</td>
<td>1 (33%)</td>
<td>2 (67%)</td>
<td>3</td>
</tr>
<tr>
<td>Other</td>
<td>1 (33%)</td>
<td>2 (67%)</td>
<td>3</td>
</tr>
<tr>
<td>Total</td>
<td>58 (70%)</td>
<td>25 (30%)</td>
<td>83</td>
</tr>
</tbody>
</table>

ANS, ataxia neuropathy spectrum; CSF, cerebrospinal fluid; MCHS, myocerebrohepatopathy spectrum; MEMSA, myoclonic epilepsy, myopathy, sensory ataxia; PEO, progressive external ophthalmoplegia.
above phenotypes and were classified as “other” (1 with a Leigh-like phenotype, 1 with a mitochondrial neurogastrointestinal encephalopathy–like phenotype, and 1 with epilepsy and transient mild elevation in liver function tests; Table 2).

3.3 | Laboratory findings

Laboratory investigations (Table 3) revealed that 59% (n = 42/71) had elevated serum lactate, 61% (n = 27/54) had elevated CSF lactate, and 65% (n = 54/82) had elevated hepatic aminotransferase levels. Muscle biopsy and respiratory chain analysis showed that 53% (n = 35/66) had abnormal histological findings, defined by the presence of ragged red fibers and/or COX-negative fibers, and 47% (n = 14/30) had abnormal respiratory chain activities; the majority (71%, n = 10/14) were in individuals with raised CSF protein/albumin.

Raised CSF protein and/or albumin was found in 70% (n = 58/83) at some point during the disease course and in 65% (n = 48/73) it was present at disease onset. Seventy-one percent (n = 30/42) had abnormal CSF protein and/or albumin measured later in the disease course. The level of CSF protein increased with disease duration; a median value of 0.83 g/L (range = 0.53-6.00) at disease onset rose to 1.04 g/L (range 0.74-4.24) later. In 12 patients, longitudinal data showed that CSF protein increased with time; median CSF protein at onset was 0.94 g/L (range = 0.57-2.5), rising to 1.18 (range = 0.8-4.2) later in the disease. The frequency of abnormal elevated CSF protein according to each specific phenotype is provided in Table 2.

3.4 | CSF protein and epilepsy

Eighty percent (n = 66/83) of the study cohort had epilepsy (focal onset, focal to bilateral tonic–conic, generalized onset, myoclonic, epilepsy partialis continua, and status epilepticus), and in 76% (n = 50/66) of these, CSF protein was raised regardless of seizure type. Median total CSF protein for those with status epilepticus was 1.04 g/L (range = 0.8-2.6). Further analysis showed that 75% (n = 15/20) of those who developed epilepsy later in the disease course had raised CSF protein at disease onset and that the majority of those with abnormal raised CSF protein (85%, n = 45/53) had therapy-resistant epilepsy.

3.5 | Evidence of blood-CSF barrier dysfunction

Serum albumin and CSF albumin values taken simultaneously were available for 18 patients, allowing calculation of the Q-alb ratio. All cases showed a markedly raised Q-alb ratio, with median value = 21.5 × 10⁻³ (range = 14.2 × 10⁻³-56.8 × 10⁻³).

3.6 | Genetics findings

Pathogenic POLG variants for each case were identified either by targeted mutation analysis for specific common mutations (c.1399G>C, p.Ala467Thr and c.2243G>C, p.Trp748Ser) or by sequence analysis of all coding regions of POLG. Further analysis showed that there was no clear association between specific genotype and raised CSF protein.

3.7 | Survival analysis

Median survival time from symptom onset for those with normal CSF protein was 32 months, compared to 13 months for those with abnormal CSF protein. Although not statistically significant (P = .08), Kaplan-Meier curve analysis showed a clear trend of worse survival for those with abnormal CSF protein (Figure S1).

4 | DISCUSSION

Our study evaluated the question of whether POLG disease is associated with BBB dysfunction, as had been suggested by a previous histological study.²² Using clinical and laboratory data from 83 individuals, we analyzed the frequency of abnormally raised CSF protein and evaluated the integrity of the brain barrier by measuring the Q-alb ratio.²⁷,²⁸ We found that more than two-thirds of patients (70%) had raised CSF protein and/or albumin. The Q-alb ratio was markedly raised in the 18 patients in whom this was measured (median value = 21.5 × 10⁻³), indicating a major dysfunction in the BBB. When compared with other disorders in which BBB dysfunction occurs, the Q-alb ratio was among the highest recorded, suggesting that POLG-related disease profoundly affects BBB integrity (Table 1).

---

**TABLE 3** Major laboratory findings in patients with POLG-related diseases

<table>
<thead>
<tr>
<th>Laboratory test</th>
<th>Percentage, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevated blood lactate</td>
<td>59% (n = 42/71)</td>
</tr>
<tr>
<td>Elevated hepatic aminotransferase</td>
<td>65% (n = 54/82)</td>
</tr>
<tr>
<td>Elevated CSF lactate</td>
<td>61% (n = 27/54)</td>
</tr>
<tr>
<td>Elevated CSF protein</td>
<td>70% (n = 58/83)</td>
</tr>
<tr>
<td>Muscle pathology (RRF, COX)</td>
<td>53% (n = 35/66)</td>
</tr>
<tr>
<td>Abnormal RC activities</td>
<td>47% (n = 14/30)</td>
</tr>
</tbody>
</table>

COX, cytochrome oxidase; CSF, cerebrospinal fluid; RC, respiratory chain; RRF, ragged red fibers.
Furthermore, our results showed that there was a progressive deterioration in the BBB integrity, as both the proportion of those with abnormal raised CSF protein and the actual CSF protein value increased with time.

When we compared the proportion of individuals with abnormal CSF protein and/or albumin to those having abnormalities of more commonly used biomarkers, we found that the proportion of those with elevated protein/albumin was higher (Table 3). This suggests that elevated CSF protein has a higher diagnostic sensitivity for POLG-related disease than lactate or the other commonly used biomarkers.

The presence of raised CSF protein was particularly common in patients with early onset, severe disease phenotypes (eg, Alpers, MCHS, and MEMSA phenotypes; Table 2). The median survival time from symptom onset for those with raised CSF protein was markedly decreased (13 months) compared to those with normal CSF protein (32 months). Elevated CSF protein showed a clear association with disease severity and with the presence of epilepsy, another major prognostic factor. Our analysis showed that 76% of POLG patients with epilepsy had raised CSF protein irrespective of seizure type; that is, because patients with focal seizures also develop status epilepticus, it is not possible from our data to assess whether one seizure type was associated with higher CSF protein. Interestingly, the presence of elevated CSF protein, and thus the possibility of BBB dysfunction, preceded the onset of the seizures (n = 15/20). Our study demonstrates, therefore, not only the diagnostic relevance of measuring CSF protein, but also its clinical importance as a biomarker in the early identification of patients with a high risk of developing epilepsy.

The relationship between BBB disruption and epilepsy has been described both in animal models and in patients. Large molecular proteins such as albumin that cross an impaired BBB can be taken up by neurons or astrocytes; uptake into neurons occurs by unknown mechanisms, but entry into astrocytes is via the TGF-β receptor. Uptake is followed by downregulation of extracellular potassium buffering capacity, which facilitates N-methyl-D-aspartate receptor–mediated neuronal hyperexcitability and the release of pro-inflammatory cytokines. All of these mechanisms may either lead to seizures or lower the threshold for seizure initiation. In addition, manipulating mitochondrial function in vitro by inhibition of complex I with rotenone, impairing ATP production using carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone, or inhibiting complex V with oligomycin can also produce rapid changes in BBB permeability. Furthermore, the same study demonstrated that inhibition of mitochondrial respiratory chain activity in mice, by epidural administration of rotenone, impaired BBB integrity and was associated with marked increase in BBB permeability.

Based on our findings and work by others, we suggest a potential mechanism: POLG mutations induce a mitochondrial dysfunction that leads to disruption of the BBB tight junctions and leakage of proteins such as albumin. Uptake of proteins by astrocytes and neurons initiates a cascade of events that contribute to seizure development (Figure 1) and subsequent worsening of the BBB dysfunction. Furthermore, we believe that the raised CSF protein is itself evidence of impaired BBB integrity and a valuable biomarker that can identify those at high risk of developing epilepsy and, by extrapolation, those with a poor prognosis.

Based on our findings, we recommend that CSF protein and Q-alb status are measured in all patients presenting with undiagnosed encephalopathy, and that those with POLG-related disease with raised CSF protein are closely monitored with frequent electroencephalographic recordings to facilitate early recognition and immediate seizure treatment.

5 | ETHICAL PUBLICATION STATEMENT

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. The ethical approved for the study was obtained from the Regional Committee for Medical and Health Research Ethics, Western Norway (REK 2014/1783-4). Each participating country had obtained approval from the local ethical committee. The study was registered as an audit at Great Ormond Street Hospital, London, UK (registration number 1675).

ACKNOWLEDGMENTS

This work was supported by grants from the Western Norway Regional Health Authority (Helse-Vest, grant 911944). P.I. is supported by a grant from the special governmental subsidy for health sciences research of Helsinki University Hospital. We thank adjunct professor Geir Egil Eide, Department of Global Public Health and Primary Care, Bergen University, Bergen, Norway for his help with the statistical analysis.

DISCLOSURE

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
REFERENCES

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.